

**AMENDMENTS TO THE CLAIMS**

This listing of claims will replace all prior versions, and listings, of claims in the application. In amendments to the claims, additions are represented by underlining and deletions are represented by ~~striketrough~~ or, in cases of five characters or fewer, by [[double brackets]].

**LISTING OF CLAIMS**

1-54. (canceled)

55. (previously presented) Dopamine gluconamide or a pharmaceutically acceptable salt thereof.

56. (previously presented) A process for making the dopamine gluconamide of claim 55 or the pharmaceutically acceptable salt thereof, the process comprising the steps of:

- a) reacting gluconolactone and 3-hydroxytyramine, and
- b) collecting the dopamine gluconamide or the pharmaceutically acceptable salt thereof.

57. (previously presented) A method for treating Parkinson's disease in a subject diagnosed with a need thereof, comprising the step of administering to the subject the dopamine gluconamide of claim 55 or the pharmaceutically acceptable salt thereof in an amount effective to treat the Parkinson's disease in the subject.

58. (previously presented) Dopamine gluconamine or a pharmaceutically acceptable salt thereof.

59. (previously presented) A process for making the dopamine gluconamine of claim 58 or the pharmaceutically acceptable salt thereof, the process comprising the steps of:

- a) providing dopamine gluconamide,
- b) protecting the aromatic hydroxyl groups of the dopamine gluconamide, and

c) reducing the protected dopamine gluconamide to form the dopamine gluconamine or the pharmaceutically acceptable salt thereof.

60. (previously presented) A method for treating Parkinson's disease in a subject diagnosed with a need thereof, comprising the step of administering to the subject the dopamine gluconamine of claim 58 or pharmaceutically acceptable salt thereof in an amount effective to treat the Parkinson's disease in the subject.

61-75. (canceled)